A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

This study has been completed.
Chinese Academy of Sciences
Information provided by:
Kunming Medical University
ClinicalTrials.gov Identifier:
First received: June 20, 2008
Last updated: June 24, 2011
Last verified: June 2011

The purpose of this study is:

  1. to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD);
  2. find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE).
  3. find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD
  4. to find possible predispose to MDD
  5. to explore the DNA methylation status in depression;

Condition Intervention
Depression Secondary to Other Disease
Drug: Escitalopram

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Health Services Research
Official Title: A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

Resource links provided by NLM:

Further study details as provided by Kunming Medical University:

Primary Outcome Measures:
  • change of fMRI after medication [ Time Frame: baseline, 4 weeks, 8 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 50
Study Start Date: June 2008
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A,1
A: Escitalopram, 20 mg/day,8weeks
Drug: Escitalopram
A,1: Escitalopram, oral, 20 mg/day, 8 weeks

Detailed Description:
  1. to explore the pathology of depression
  2. to identify the difference between MDD and depression secondary to other disease ,especially autoimmune disease
  3. to explore the effect of gene-environment interaction on the epigenetic regulation of the depression

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • DSM-IV Major Depression or Dysthymia
  • Age 18-65
  • Physically healthy
  • Drug-free

Exclusion Criteria:

  • Body metal (e.g., wire stitches, screws in bones, stainless steel hips)
  • History of Psychosis or Epilepsy
  • Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
  • Bipolar I
  • Need for wash-out from effective treatment in order to participate
  • Pregnant
  • High suicide risk
  • Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00703742

China, Yunnan
The First Affiliated Hospital of Kunming Medical College
Kunming, Yunnan, China, 650031
Sponsors and Collaborators
Kunming Medical University
Chinese Academy of Sciences
Study Director: Xu Xiufeng Kunming Medical University
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Kunming Medical College
ClinicalTrials.gov Identifier: NCT00703742     History of Changes
Other Study ID Numbers: Kunming MC 
Study First Received: June 20, 2008
Last Updated: June 24, 2011
Health Authority: China: Ethics Committee

Additional relevant MeSH terms:
Depressive Disorder
Behavioral Symptoms
Mental Disorders
Mood Disorders
Antidepressive Agents
Anti-Dyskinesia Agents
Antidepressive Agents, Second-Generation
Antiparkinson Agents
Autonomic Agents
Cholinergic Agents
Cholinergic Antagonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors

ClinicalTrials.gov processed this record on May 26, 2016